Almost a third of the members of a government panel that voted last week to let the pain pills Celebrex, Bextra and Vioxx stay on the market recently consulted for the makers of the drugs

“Without the votes of those 10 members, the committee would have voted 12 to 8 that Bextra should be withdrawn and 14 to 8 that Vioxx should not return to the market. The 10 advisers with company ties voted 9 to 1 to keep Bextra on the market and 9 to 1 for Vioxx’s return.”

Related posts:

1. Side effects of life
2. That damn RUC
3. Should Darvon be withdrawn? The implications of banning propoxyphene
4. Bring Vioxx back?
5. The disruptive family
6. Google and Microsoft Health
7. Fallout from the Zelnorm recall

  Follow on Twitter   Subscribe

Tagged as: drugs